This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Apr;15(4):369-70.

doi: 10.1016/S1470-2045(14)70079-8. Epub 2014 Feb 27.

Community experience of vemurafenib for BRAF(V600) melanoma

Affiliations

PMID: 24582506
DOI: 10.1016/S1470-2045(14)70079-8

Comment

Community experience of vemurafenib for BRAF(V600) melanoma

Peter Hersey. Lancet Oncol. 2014 Apr.

. 2014 Apr;15(4):369-70.

doi: 10.1016/S1470-2045(14)70079-8. Epub 2014 Feb 27.

Author

Affiliation

¹ Kolling Institute, and Melanoma Institute of Australia, University of Sydney, NSW 2065, Australia. Electronic address: peter.hersey@sydney.edu.au.

PMID: 24582506
DOI: 10.1016/S1470-2045(14)70079-8

No abstract available

PubMed Disclaimer

Comment on

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU. Larkin J, et al. Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27. Lancet Oncol. 2014. PMID: 24582505 Clinical Trial.

Similar articles

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU. Larkin J, et al. Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27. Lancet Oncol. 2014. PMID: 24582505 Clinical Trial.
[Treatment of metastatic melanoma with BRAF inhibitors].
Hafner C. Hafner C. Hautarzt. 2011 Sep;62(9):696-8. doi: 10.1007/s00105-011-2232-8. Hautarzt. 2011. PMID: 21863388 German. No abstract available.
BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, Pages C, Roux J, Porcher R, Tost J, Mourah S. Lebbé C, et al. Melanoma Res. 2014 Aug;24(4):415-8. doi: 10.1097/CMR.0000000000000088. Melanoma Res. 2014. PMID: 24933605 No abstract available.
Overcoming metastatic melanoma with BRAF inhibitors.
Hong S, Hong S, Han SB. Hong S, et al. Arch Pharm Res. 2011 May;34(5):699-701. doi: 10.1007/s12272-011-0521-5. Arch Pharm Res. 2011. PMID: 21656352 Review.
Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J, Larkin J. Martin-Liberal J, et al. Future Oncol. 2015;11(4):579-89. doi: 10.2217/fon.14.252. Future Oncol. 2015. PMID: 25686114 Review.

See all similar articles

Cited by

Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report.
Iafolla MA, Ramsay J, Wismer J, McWhirter E. Iafolla MA, et al. SAGE Open Med Case Rep. 2019 May 16;7:2050313X19847358. doi: 10.1177/2050313X19847358. eCollection 2019. SAGE Open Med Case Rep. 2019. PMID: 31205706 Free PMC article.
Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib.
Nowara E, Huszno J, Slomian G, Nieckula J. Nowara E, et al. Postepy Dermatol Alergol. 2016 Feb;33(1):52-6. doi: 10.5114/pdia.2015.48045. Epub 2016 Feb 29. Postepy Dermatol Alergol. 2016. PMID: 26985180 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program